Neuromyelitis Optica Spectrum Disorder  >>  Enspryng (satralizumab)  >>  Phase 4
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Enspryng (satralizumab) / Roche
SAkuraBonsai, NCT05269667: A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention

Terminated
4
4
Europe, Canada, Japan, US, RoW
Satralizumab 120 mg
Hoffmann-La Roche, Chugai Pharmaceutical Co.
Neuromyelitis Optica Spectrum Disorder, NMOSD
10/23
10/23

Download Options